FDA Grants Fast Track Designation to AFM13 Plus AlloNK for Relapsed/Refractory Hodgkin Lymphoma
The FDA has granted fast track designation to the first-in-class innate cell engager AFM13 plus AlloNK for the treatment of patients with relapsed/refractory Hodgkin lymphoma.
Source: onclive.com